Arsenic trioxide for acute promyelocytic leukemia in a patient on chronic hemodialysis.

Acute promyelocytic leukemia Arsenic trioxide Hemodialysis

Journal

Leukemia research reports
ISSN: 2213-0489
Titre abrégé: Leuk Res Rep
Pays: England
ID NLM: 101608906

Informations de publication

Date de publication:
2022
Historique:
received: 05 04 2021
revised: 10 01 2022
accepted: 22 03 2022
entrez: 4 4 2022
pubmed: 5 4 2022
medline: 5 4 2022
Statut: epublish

Résumé

Acute promyelocytic leukemia (APL) is a rare acute leukemia generally considered curable with all-trans retinoic acid (ATRA) and arsenic trioxide (ATO). Some patients have co-morbidities that may limit the use of these agents and therefore impact curability. Adverse effects of ATO include life-threatening electrocardiographic abnormalities. ATO and its metabolites are partially excreted in the urine, and it is unclear to what extent ATO pharmacokinetics are impacted by hemodialysis. We present a patient on chronic hemodialysis successfully treated with ATO and ATRA for newly diagnosed APL. Complete molecular remission was achieved after induction and several drug-related toxicities were managed.

Identifiants

pubmed: 35371914
doi: 10.1016/j.lrr.2022.100304
pii: S2213-0489(22)00016-4
pmc: PMC8968060
doi:

Types de publication

Case Reports

Langues

eng

Pagination

100304

Informations de copyright

© 2022 The Author(s).

Déclaration de conflit d'intérêts

None

Références

Leuk Lymphoma. 2021 Mar;62(3):696-702
pubmed: 33106056
Haematol Blood Transfus. 1989;32:88-96
pubmed: 2696695
J Oncol Pharm Pract. 2016 Aug;22(4):646-51
pubmed: 25972392
Am J Dis Child. 1970 Oct;120(4):367-71
pubmed: 5493839
J Clin Oncol. 2003 Dec 15;21(24):4642-9
pubmed: 14673054
Eur J Haematol. 2015 Oct;95(4):331-5
pubmed: 25600167
Pacing Clin Electrophysiol. 1990 Feb;13(2):164-70
pubmed: 1689832
N Engl J Med. 1980 Nov 6;303(19):1096-8
pubmed: 7421915
J Med Case Rep. 2012 Oct 18;6:355
pubmed: 23078653
N Engl J Med. 2013 Jul 11;369(2):111-21
pubmed: 23841729
Blood. 2019 Apr 11;133(15):1630-1643
pubmed: 30803991
Cancer Cell. 2017 Nov 13;32(5):552-560
pubmed: 29136503

Auteurs

Jose Tinajero (J)

Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, United States.

Khaled El-Shami (K)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.

Xiaojun Wu (X)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.

B Douglas Smith (BD)

The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MD, United States.

Matthew J Newman (MJ)

Department of Pharmacy, The Johns Hopkins Hospital, Baltimore, MD, United States.

Classifications MeSH